Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Average Rating of “Buy” by Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been assigned a consensus recommendation of “Buy” from the ten analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $15.3750.

IVA has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Cantor Fitzgerald initiated coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company.

Hedge Funds Weigh In On Inventiva

A number of large investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP acquired a new position in shares of Inventiva during the 4th quarter worth approximately $18,600,000. ADAR1 Capital Management LLC bought a new stake in shares of Inventiva in the fourth quarter valued at about $12,601,000. Millennium Management LLC boosted its holdings in Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after purchasing an additional 2,540,540 shares during the period. UBS Group AG grew its position in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after buying an additional 2,634,580 shares in the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new position in Inventiva in the fourth quarter valued at about $12,090,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Stock Down 7.0%

Shares of NASDAQ IVA opened at $4.14 on Friday. Inventiva has a 1 year low of $3.35 and a 1 year high of $7.98. The firm’s 50-day moving average is $4.57 and its 200-day moving average is $4.96.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.